References
Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92:34–48
Happe S, Husstedt IW (2000) Successful treatment of acute encephalomyelitis associated with common variable immunodeficiency syndrome (CVID): case report and review of the literature. J Neurol 247:562–565
Narula S, LaRosa DF, Kamoun M, Dalmau J, Levinson AI (2007) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution. Ann Allergy Asthma Immunol 98:483–489
Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS (2008) Common variable immunodeficiency: a new look at an old disease. Lancet 372:489–502
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302
Rieckmann P, Heidenreich F, Sailer M, Zettl UK, Zessack N, Hartung HP, Gold R (2012) Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord 5:3–12
Rudge P, Webster AD, Revesz T, Warner T, Espanol T, Cunningham-Rundles C, Hyman N (1996) Encephalomyelitis in primary hypogammaglobulinemia. Brain 119(Pt 1):1–15
Scotton PG, Vaglia A, Carniato A, Marchiori GC (1998) Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency. Clin Infect Dis 26:215–216
Snyder MD, Storch GA, Clifford DB (2005) Atypical PML leading to a diagnosis of common variable immunodeficiency. Neurology 64:1661
Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F (2013) The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 19:1826–1840
Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075–1080
Conflicts of interest
HCL has received personal compensations and/or grant support from Baxter, Celgene, CSL Behring, Fresenius, Grifols, and Novartis. MS has received personal and/or institutional compensations from Almirall, Baxter, Bayer HealthCare, Boehringer Ingelheim, Biogen Idec, CSL Behring, Grifols, Merck Serono, Novartis, Sanofi-Genzyme, and Teva.
Ethical standard
This letter was written in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehmann, H.C., Krüger, K., Fink, G.R. et al. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J Neurol 262, 771–773 (2015). https://doi.org/10.1007/s00415-014-7620-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-014-7620-4